Europe Wakes Up: The Coming Alliance Boom
Mid-size European drug companies have always been reluctant suitors when it comes to doing deals with US biotech companies. But judging by attendance at this year's Euro-Biotech Forum, they've gotten religion. Late-stage deal-making, still favored, is down, while more companies are willing to do research-stage deals.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.